Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | NAMPT | P43490 | 4/20 | 0.48 |
| ▸ | MAPT | P10636 | 12/20 | 0.48 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
| ▸ | NPY2R | P49146 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5462034 | 0.86 | NAMPT (0.56) | NPC1RAB9ANAMPTMAPTMEN1 | |
| SCHEMBL5453420 | 0.86 | P2RY1 (0.51) | NPC1RAB9ANAMPTMAPTKCNQ2 | |
| SCHEMBL5462090 | 0.84 | KMT2A (0.56) | NPC1RAB9ANAMPTMAPTKCNQ2 | |
| SCHEMBL5462047 | 0.83 | HTT (0.57) | NPC1RAB9ANAMPTMAPTMEN1 | |
| SCHEMBL5465117 | 0.82 | KMT2A (0.61) | NPC1RAB9AMAPTMEN1KMT2A | |
| SCHEMBL5454329 | 0.81 | KMT2A (0.57) | NPC1RAB9ANAMPTMAPTMEN1 | |
| SCHEMBL5460048 | 0.81 | MAPT (0.51) | NPC1RAB9ANAMPTMAPTMEN1 | |
| SCHEMBL5459931 | 0.79 | MEN1 (0.63) | NPC1RAB9ANAMPTMAPTMEN1 | |
| SCHEMBL5459612 | 0.78 | NPC1 (0.58) | NPC1RAB9ANAMPTMAPTMEN1 | |
| SCHEMBL5463537 | 0.78 | MAPT (0.59) | NPC1RAB9ANAMPTMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070249620-A1 | Urea Derivative | SANKYO COMPANY, LIMITED (JP) | 2007-10-25 | — | — | US | disclosed |
| EP-1764360-A1 | UREA DERIVATIVE | Sankyo Company, Limited (JP) | 2007-03-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249620-A1 | Urea Derivative | UGP2, SLC14A1, DGAT1 | NPC1 1089/4885RAB9A 1528/4885NAMPT 324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.